$2 Million Initial Investment Completed
SILVER SPRING, Md., Feb. 20, 2014 (GLOBE NEWSWIRE) — PharmaCyte Biotech, Inc. (NVLX), an international biotechnology company providing cell and gene therapy solutions for the treatment of deadly diseases, announced today that it has entered into a stock purchase agreement with Lincoln Park Capital Fund, LLC (Lincoln Park), a Chicago-based institutional investor. Lincoln Park initially purchased 8 million shares of PharmaCyte Biotech’s common stock at $0.25 per share for $2 million and has committed to invest, at the sole option of PharmaCyte Biotech, up to an additional $25 million of equity capital over the term of the purchase agreement. The proceeds from this investment will be used for PharmaCyte Biotech’s late-stage clinical trials in advanced inoperable pancreatic cancer, for research into the use of constituents of marijuana in the emerging medical marijuana arena and for general operating purposes.
Kenneth L. Waggoner, the CEO and President of PharmaCyte Biotech, commented, “Our stock purchase agreement with Lincoln Park gives PharmaCyte Biotech the flexibility to access capital over time at prevailing market prices and as our needs arise. The initial funding helps us to proceed with our planned late-stage pancreatic cancer clinical trials. The $2 million initial investment also reflects the commitment to PharmaCyte Biotech and our live-cell encapsulation platform for developing treatments for cancer and diabetes.”
During the 36-month term of the stock purchase agreement, PharmaCyte Biotech, at its sole discretion, has the right to sell Lincoln Park up to an additional $25 million of PharmaCyte Biotech common stock in amounts as described in the agreement and subject to certain conditions which include the effectiveness of a registration statement with the U.S. Securities and Exchange Commission (SEC) covering the sale of the shares that may be issued to Lincoln Park. PharmaCyte Biotech controls the timing and amount of any future investment. Lincoln Park is obligated to make purchases if and when PharmaCyte Biotech decides.
Under the terms of the stock purchase agreement, there are no upper limits on the price Lincoln Park may pay to purchase PharmaCyte Biotech’s common stock. The purchase price of the shares related to any future investments will be based on the prevailing market prices of PharmaCyte Biotech’s shares immediately preceding a notice of sale to Lincoln Park. Lincoln Park has agreed not to cause or engage in any direct or indirect short selling or hedging of PharmaCyte Biotech’s common stock. The stock purchase agreement may be terminated by PharmaCyte Biotech at any time at its sole discretion and without any monetary cost to PharmaCyte Biotech.
A more detailed description of the stock purchase agreement is set forth in the PharmaCyte Biotech’s Current Report on Form 8-K already filed with the SEC and which PharmaCyte Biotech encourages be reviewed carefully.
This press release does not constitute an offer to sell or a solicitation of an offer to buy the securities in any offering, nor will there be any sale of securities of PharmaCyte Biotech in any jurisdiction in which such offer solicitation or sale are unlawful prior to registration or qualification under securities laws of any such jurisdiction.
About PharmaCyte Biotech:
PharmaCyte Biotech is a biotechnology company focused on developing and preparing to commercialize treatments for cancer and diabetes based upon a proprietary cellulose-based live-cell encapsulation technology called Cell-in-a-Box(TM). This unique technology will be used as a platform upon which treatments for several types of cancer, including advanced, inoperable pancreatic cancer, and diabetes are being built. PharmaCyte Biotech’s treatment for pancreatic cancer involves the use of the widely used anticancer prodrug ifosfamide together with encapsulated live cells that convert ifosfamide into its active or “cancer-killing” form. PharmaCyte Biotech’s subsidiary, Medical Marijuana Sciences, Inc., is dedicated to the development of cancer treatments based upon chemical constituents of marijuana known as cannabinoids. To do so, it will examine ways to exploit the benefits of Cell-in-a-Box(TM) technology in optimizing the anticancer effectiveness of cannabinoids against cancers while minimizing or outright eliminating the debilitating side effects usually associated with cancer treatments. This provides Medical Marijuana Sciences a unique opportunity to develop “green” approaches to fighting deadly cancers, such as those of the pancreas, brain, breast and prostate, that affect hundreds of thousands of individuals worldwide every year.
About Lincoln Park Capital:
Lincoln Park is an institutional investor headquartered in Chicago, Illinois. Lincoln Park’s experienced professionals manage a portfolio of investments in public and private entities. These investments are in a wide range of companies and industries emphasizing life sciences, specialty financing, energy and technology. Lincoln Park’s investments range from multiyear financial commitments to fund growth to special situation financings to long-term strategic capital offering companies certainty, flexibility and consistency. For more information, visit www.lpcfunds.com.
This press release may contain forward-looking statements regarding PharmaCyte Biotech and its future events and results that are subject to the safe harbors created under the Securities Act of 1933, as amended, and the Securities Exchange Act of 1934, as amended. All statements, other than statements of historical facts, included in this press release regarding PharmaCyte Biotech’s financial position, business strategy, plans and objectives of management for future operations and business conditions are forward-looking statements.
Forward-looking statements involve inherent risks and uncertainties. Important factors, many of which are beyond the control of PharmaCyte Biotech, that could cause actual results to differ materially from those set forth in the forward-looking statements include general economic or business conditions, changes in legislation or regulatory requirements, conditions of the securities markets, PharmaCyte Biotech’s ability to raise capital, changes in accounting principles, policies or guidelines, financial or political instability and other economic, competitive, governmental, regulatory and technical factors affecting the plans, operations, products and services of PharmaCyte Biotech and its subsidiaries.
PharmaCyte Biotech has based these forward-looking statements on its current expectations and assumptions about future events. While management considers these expectations and assumptions to be reasonable, they are inherently subject to significant business, economic, competitive, regulatory and other risks, contingencies and uncertainties, most of which are difficult to predict and many of which are beyond the control of PharmaCyte Biotech. PharmaCyte Biotech does not assume any obligations to update any of these forward-looking statements.
More information about PharmaCyte Biotech and Medical Marijuana Sciences can be found at www.nuvilex.com and www.medicalmarijuanasciences.com. It can also be obtained by contacting Investor Relations.
Investor Relations Contacts:
Marmel Communications, LLC